The 2015 FDA 'Low T' Action
FDA Labeling Restriction and the End of the AndroGel 'Low T' Campaign
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- FDA Safety Communication & Label Change (March 2015)
Reference only. Not medical advice.
What can go wrong
The 2015 cardiovascular warning created years of clinical caution and litigation based on observational data later not confirmed by randomized evidence. Conversely, the marketing restriction did little to slow off-label, age-based prescribing, which migrated to telehealth platforms operating outside the original DTC advertising channels.
This is something to take to a clinician. The Atlas can tell you what is known about the 2015 fda 'low t' action in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
In March 2015 the FDA ordered manufacturers of all approved testosterone products to revise labeling to state clearly that these products are approved ONLY for men with hypogonadism caused by an associated underlying medical condition, not for low testosterone due to aging alone. The agency simultaneously required a warning about possible increased cardiovascular risk (based on the observational data available at the time) and acted against the 'Low T' direct-to-consumer advertising that AbbVie had built around AndroGel since 2008, which the FDA characterized as promoting an unapproved, age-based use.
The day the regulator told the industry to stop selling testosterone as an antidote to aging.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
The action was an FDA labeling and safety communication, not a drug approval or withdrawal. It narrowed the on-label indication language and added a cardiovascular caution, reshaping what manufacturers could legally claim and advertise.
What the action did and did not do
The 2015 action restricted labeling and marketing; it did not ban prescribing. Physicians retained the ability to prescribe off-label, and the telehealth industry that expanded after COVID-era deregulation built much of its model on exactly the age-related and symptom-based prescribing the FDA had declined to endorse. The cardiovascular warning attached in 2015 rested on observational signals; it was later substantially revised after the TRAVERSE randomized trial reported in 2023, with the FDA removing the cardiovascular framing in February 2025.
Safety in detail
Approved testosterone therapy is indicated for hypogonadism from an underlying medical condition. Use for age-related decline is off-label and requires evaluation and monitoring by a qualified physician; testosterone therapy carries documented health risks.
What it does to fertility
Indirect, by restricting approved use to genuine hypogonadism, the action implicitly targeted inappropriate prescribing, including to men for whom fertility suppression from exogenous testosterone would be an avoidable harm.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Confirmation of an underlying medical cause of hypogonadism before therapy
- Documentation of two low morning testosterone values
What people get wrong
Often saidThe FDA approved testosterone for the symptoms of aging
ActuallyThe FDA explicitly stated the opposite in 2015, approved use is limited to hypogonadism from an underlying medical condition, not aging.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Date
- March 2015
- Scope
- All approved testosterone products
- Approved use clarified
- Hypogonadism from a medical condition
- Not approved for
- Age-related decline alone
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about The 2015 FDA 'Low T' Action. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
FDA Drug Safety Communication2015
Restricted testosterone labeling to hypogonadism from a medical condition; required CV warning